Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 701–800 of 1,000
Bensimon, A. G., Zhou, Z., Jenkins, M. D., Song, Y., Gao, W., Signorovitch, J., Krepler, C., Scherrer, E., Wang, J., & Aguiar‐Ibáñez, R. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00922-6 · Cited by 23
Popp, F., Capino, I., Bartels, J., Damanakis, A. I., Li, J., Datta, R. R., Löser, H., Zhao, Y., Quaas, A., Lohneis, P., et al. (2021) · Cancers · doi:10.3390/cancers13112689 · Cited by 23
Newcomer, K., Robbins, K. J., Perone, J., Hinojosa, F. L., Chen, D., Jones, S., Kaufman, C. K., Weiser, R., Fields, R. C., & Tyler, D. S. (2021) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2021.101030 · Cited by 26
The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers
Xiang, Z., Hua, M., Zhou, H., Biao, H., Zhu, C., Zhai, G., & Wu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844001 · Cited by 24
“Exosomes derived from hMSCs could similarly enhance GC resistance (44).”
BackgroundTissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Plunkett, K. R., Armitage, J. D., Inderjeeth, A., McDonnell, A. M., Waithman, J. C., & Lau, P. K. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1048758 · Cited by 25
Immune checkpoint inhibitors as a threat to reproductive function: A systematic review
Tuerxun, H., Zhao, Y., Li, Y., Liu, X., Wen, S., Cao, J., Cao, J., & Zhao, Y. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104064 · Cited by 22
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancers · doi:10.3390/cancers15164176 · Cited by 27
“The approvals for single-agent pembrolizumab and nivolumab in stage III/IV disease were based on data from KEYNOTE 054 and Checkmate 238, which demonstrated an improvement in relapse-free survival (RFS) and distant-metastasis-free survival (DMFS) with the administration of PD-1 inhibition over a placebo [72] or CTLA-4…”
MethodImpact of initial stage on metastatic melanoma survival
Wilson, M. A., Zhong, J., Rosenbaum, B. E., Utter, K., Moran, U., Darvishian, F., Polsky, D., Berman, R. S., Shapiro, R. L., Pavlick, A. C., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000526 · Cited by 24
Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma
Lundberg, M., Haapaniemi, A., Hagström, J., Juteau, S., Hernberg, M., Mäkitie, A. A., & Vento, S. I. (2019) · Rhinology Journal · doi:10.4193/rhin18.123 · Cited by 23
Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanoma
Angeles, C. V., Kang, R., Shirai, K., & Wong, S. L. (2019) · British journal of surgery · doi:10.1002/bjs.11149 · Cited by 23
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma
Sabbatino, F., Scognamiglio, G., Liguori, L., Marra, A., Anniciello, A. M., Polcaro, G., Col, J. D., Caputo, A., Peluso, A. L., Botti, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561390 · Cited by 22
Boer, F. L., Eikelder, M. T., van Geloven, N., Kapiteijn, E., Gaarenstroom, K. N., Hughes, G., Nooij, L. S., Jozwiak, M., Tjiong, M. Y., Hullu, J. A. D., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.018 · Cited by 22
Han, Y., Wang, J., & Xu, B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103376 · Cited by 24
Long, G. V., Garnett‐Benson, C., Dolfi, S. C., Ascierto, P. A., Guo, J. X., Tarhini, A. A., Chandra, S., Muñoz‐Couselo, E., Vecchio, M. D., de Melo, A. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04032-8 · Cited by 21
Self-citationNamikawa, K., Aung, P. P., Milton, D. R., Tetzlaff, M. T., Torres-Cabala, C. A., Curry, J. L., Nagarajan, P., Ivan, D. S., Ross, M. I., Gershenwald, J. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1194 · Cited by 24
Donini, M., Buti, S., Massari, F., Mollica, V., Rizzo, A., Montironi, R., Bersanelli, M., & Santoni, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1770601 · Cited by 23
“pembrolizumab [107] and nivolumab [108] as adjuvant thera-”
BackgroundZucali, P. A., Cordua, N., D’Antonio, F., Borea, F., Perrino, M., Vincenzo, F. D., & Santoro, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568279 · Cited by 25
Ali, Z., Zafar, M. U., Wolfe, Z., Akbar, F., & Lash, B. W. (2020) · Cureus · doi:10.7759/cureus.11246 · Cited by 21
“The most common immune-related adverse events (irAEs) reported in phase III trials of these agents include fatigue, pruritis, diarrhea, rash, nausea, increased lipase level, and hypothyroidism [5-6].”
BackgroundWitjes, J. A., Galsky, M. D., Gschwend, J. E., Broughton, E. I., Braverman, J., Nasroulah, F., Maira-Arce, M., Ye, X., Shi, L., Guo, S., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.02.003 · Cited by 21
“Moreover, in another phase 3 trial (CheckMate 238), adjuvant nivolumab prolonged recurrence-free survival in patients with resected stage III or IV melanoma, as compared with ipilimumab, without affecting HRQoL [39].”
BackgroundGao, Z., Wang, L., Song, Z., Ren, M., Yang, Y., Li, J., Shen, K., Li, Y., Ding, Y., Yang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954039 · Cited by 22
“Trials of PD-1 blockade focusing on cutaneous melanoma have demonstrated long-term objective response rates (ORR) of approximately 45%, with more than 40% patients surviving for over 5 years (19, 58).”
BackgroundWong, C., Lam, T.-H., Liao, S.-Y., Lau, Y., Tse, H., & So, B. Y. F. (2023) · Biomedicines · doi:10.3390/biomedicines11010107 · Cited by 23
Davoodi‐Moghaddam, Z., Jafari‐Raddani, F., Noori, M., & Bashash, D. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101636 · Cited by 21
Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 24
“Nivolumab binds to PD-1 and inhibits binding of both PD-L1 and PD-L2, whereas atezolizumab binds selectively to PD-L1, thereby allowing immune response escape through PD-1/PD-L2 interaction [62].”
BackgroundLodde, G. C., Hassel, J. C., Wulfken, L. M., Meier, F. E., Mohr, P., Kähler, K. C., Hauschild, A., Schilling, B., Loquai, C., Berking, C., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112957 · Cited by 21
Xu, X., Wang, M.-D., Xu, J.-H., Fan, Z., Diao, Y., Chen, Z., Jia, H., Liu, F., Zeng, Y., Wang, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1322233 · Cited by 25
Immune Checkpoint Inhibitors in Melanoma and HIV Infection
Marra, A., Scognamiglio, G., Peluso, I., Botti, G., Fusciello, C., Filippelli, A., Ascierto, P. A., Pepe, S., & Sabbatino, F. (2017) · The Open AIDS Journal · doi:10.2174/1874613601711010091 · Cited by 21
“[55] Weber J, Mandala M, Del Vecchio M, et al.”
BackgroundSelf-citationLuke, J. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0876 · Cited by 21
“At the same time, the benefits of BRAF-MEK and immune checkpoint inhibitors are being translated into earlier use in the adjuvant setting [71, 72], where they are improving recurrence-free survival.”
BackgroundNi, X., Xing, Y., Sun, X., & Suo, J. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.05.007 · Cited by 23
Cutaneous Melanoma – A Review of Systemic Therapies
Lee, K., & Nathan, P. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3496 · Cited by 24
“It is worth noting that patients with high risk (primary tumour > 4 mm, or > 2 mm with ulceration) but node negative tumours were excluded from the phase III clinical trials that evaluated nivolumab, ipilimumab and the targeted therapy doublet of dabrafenib and trametinib (62, 64, 65).”
BackgroundVerver, D., Rekkas, A., Garbe, C., Klaveren, D. V., van Akkooi, A. C. J., Rutkowski, P. L., Powell, B. W. E. M., Robert, C., Testori, A., van Leeuwen, B. L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.022 · Cited by 22
Self-citationO’Donnell, J. C., Le, T. K., Dobrin, R., Higashi, M. K., Pereira, A., Wagner, S., Yang, A. S., & Hukkelhoven, M. (2020) · Future Oncology · doi:10.2217/fon-2020-0591 · Cited by 21
Ouyang, T., Cao, Y., Kan, X., Chen, L., Ren, Y., Sun, T., Yan, L., Xiong, B., Liang, B., & Zheng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621639 · Cited by 23
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 24
“For example, treatment with ICIs targeting CTLA-4 or another immune checkpoint, programmed cell death 1 (PD-1), has been shown to be effective in advanced melanoma [31,32], colon cancer with mismatchrepair deficiency [33], Hodgkin lymphoma [34], and renal cell carcinoma [35].”
BackgroundGezgin, G., Visser, M., Ruano, D., Santegoets, S. J. A. M., de Miranda, N. F. C. C., van der Velden, P. A., Luyten, G. P. M., van der Burg, S. H., Verdegaal, E. M. E., & Jager, M. J. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100132 · Cited by 22
Surgery for Metastatic Melanoma: an Evolving Concept
Testori, A., Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0847-6 · Cited by 23
Acral melanoma in skin of color: current insights and future directions: a narrative review
Nadelmann, E., Singh, A., Abbruzzese, M., Adeuyan, O., Kenchappa, D., Kovrizhkin, K., Lightman, M., Samouha, A., Tao, K., Yun, J., et al. (2025) · Cancers · doi:10.3390/cancers17030468 · Cited by 20
“The additive effect of socioeconomic status on survival in ethnic minorities with ALM was highlighted by a Brazilian study showing correlation of income with survival [10].”
Boada, A., Tejera‐Vaquerizo, A., Ribero, S., Puig, S., Moreno-Ramírez, D., Quaglino, P., Osella‐Abate, S., Cassoni, P., Malvehy, J., Carrera, C., et al. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.09.189 · Cited by 22
“This, together with its value when selecting patients for new adjuvant treatments [3,4] means the procedure is still valid.”
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
Gust, K. M., Rebhan, K., Resch, I., Shariat, S. F., & Necchi, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000783 · Cited by 20
Physio-pathological effects of m6A modification and its potential contribution to melanoma
Liao, Y., Han, P., Zhang, Y., & Ni, B. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02644-3 · Cited by 21
“Although progress has been made in the treatment of advanced melanoma [71, 72], there remain no proper curative treatments currently available.”
BackgroundMa, F., Wu, J., Li, F., Li, A., Lan, B., Chen, K., Di, J., Jiang, Y., Li, J., Li, N., et al. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.07.003 · Cited by 20
“When formulating guidelines for international breast cancer screening and healthcare policy making, it is necessary to consider not only the effectiveness of screening but also the cost of different screening programs 27 , 28 .”
MethodNovel strategies for immuno-oncology breakthroughs with cell therapy
Liu, H., Pan, C.-X., Song, W., Liu, D., Li, Z., & Zheng, L. (2021) · Biomarker Research · doi:10.1186/s40364-021-00316-6 · Cited by 21
Magnetic nanoparticles in theranostics of malignant melanoma
Shevtsov, M. A., Kaesler, S., Posch, C., Multhoff, G., & Biedermann, T. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00868-6 · Cited by 21
“Compared to ipilimumab, the PD-1 inhibitors reached even higher overall response rates of 30–40% [63], with less irAEs and longer relapse-free and overall survival rates [64, 65].”
BackgroundPedersen, S., Holmstroem, R. B., von Heymann, A., Tolstrup, L. K., Madsen, K. S., Petersen, M. A., Haslund, C. A., Ruhlmann, C. H. B., Schmidt, H., Johansen, C., et al. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2165449 · Cited by 24
“ally significant changes during adjuvant treatment [6,13].”
BackgroundHoellwerth, M., Koelblinger, P., Lang, R., & Harrer, A. (2023) · Life · doi:10.3390/life13020553 · Cited by 23
“, circulating tumor cells, that still may be present [4].”
BackgroundHaist, M., Stege, H. M., Rogall, F., Tan, Y., von Wasielewski, I., Klespe, K. C., Meier, F. E., Mohr, P., Kähler, K. C., Weichenthal, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007630 · Cited by 23
Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations
Shalata, W., Attal, Z. G., Solomon, A., Shalata, S., Saleh, O. A., Tourkey, L., Salamah, F. A., Alatawneh, I., & Yakobson, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115794 · Cited by 22
“This randomized, phase 3 double-blind trial investigated the use of adjuvant therapy with NIVO compared to IPI in 906 patients with resected IIB/C or IV melanoma [64].”
MethodAdvances in Immunotherapy and Targeted Therapy of Malignant Melanoma
Wang, X., Ma, S., Zhu, S., Zhu, L., & Guo, W. (2025) · Biomedicines · doi:10.3390/biomedicines13010225 · Cited by 31
“Additionally, the incidence of grade 3–4 side effects was significantly lower in the Nivolumab-treated group [34].”
Bertolli, E., Franke, V., Calsavara, V. F., de Macêdo, M. P., Pinto, C. A. L., van Houdt, W. J., Wouters, M. W. J. M., Neto, J. P. D., & van Akkooi, A. C. J. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-7038-9 · Cited by 20
Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
Chénard-Poirier, M., & Smyth, E. C. (2019) · Drugs · doi:10.1007/s40265-018-1032-1 · Cited by 23
“Therefore, combining immune checkpoint blockade with neoadjuvant, perioperative or adjuvant treatment strategies, is attractive [44, 45].”
BackgroundPavri, S. N., Han, G., Khan, S. A., & Han, D. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25445 · Cited by 23
“Importantly, given the new advances in adjuvant systemic therapies for melanoma, both adjuvant targeted therapy and adjuvant immune checkpoint inhibitor therapy, the detection of a positive SLN may provide more than just prognostic data, but may now also be an indication for adjuvant therapy.(32,33) In this study, 5‐y…”
BackgroundBiomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Rizk, E. M., Seffens, A., Trager, M. H., Moore, M. R., Geskin, L. J., Gartrell, R. D., Wong, W., & Saenger, Y. M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00475-1 · Cited by 23
van Willigen, W. W., Bloemendal, M., Boers‐Sonderen, M. J., de Groot, J. W. B., Koornstra, R. H. T., van der Veldt, A. A. M., Haanen, J. B. A. G., Boudewijns, S., Schreibelt, G., Gerritsen, W. R., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738814 · Cited by 23
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 21
Immunotherapy for older patients with melanoma: From darkness to light?
Iacono, D., Vitale, M. G., Basile, D., Pelizzari, G., Cinausero, M., Poletto, E., Pascoletti, G., & Minisini, A. M. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12917 · Cited by 22
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Huemer, F., Leisch, M., Geisberger, R., Zaborsky, N., & Greil, R. (2021) · Pharmaceuticals · doi:10.3390/ph14020089 · Cited by 24
“Meanwhile, nivolumab [70], as well as pembrolizumab [71], have been FDA approved for adjuvant melanoma therapy in stage IIIB-IV and stage III, respectively.”
BackgroundChristofyllakis, K., Pföhler, C., Bewarder, M., Müller, F. M., Thurner, L., Rixecker, T. M., VOGT, T. M., Stilgenbauer, S., Yordanova, K., & Kaddu‐Mulindwa, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.637161 · Cited by 22
“Immune checkpoint inhibitor (ICi) monotherapy with pembrolizumab or nivolumab is similarly effective in improving RFS and both agents seem to be superior to ipilimumab while being less toxic, as previously demonstrated for nivolumab in the Checkmate-238 trial (24).”
BackgroundBroman, K. K., Bettampadi, D., Pérez‐Morales, J., Sun, J. X., Kirichenko, D., Carr, M. J., Eroglu, Z., Tarhini, A. A., Khushalani, N. I., Schabath, M. B., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10570-5 · Cited by 21
Weber, J. S., Ascierto, P. A., Middleton, M. R., Hennicken, D., Zoffoli, R., Pieters, A., Amadi, A., Kupas, K., Kotapati, S., Moshyk, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.028 · Cited by 22
Self-citationFactors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 28
“associated with improved relapse-free survival, overall survival, and distant metastasis-free survival compared with placebo of stage III melanoma patients (101, 102).”
BackgroundBasak, E. A., Vermeer, N. S., de Joode, K., Hurkmans, D. P., Velthuis, D. E. M., Hoop, E. O., Schreurs, M. W. J., Bins, S., Koolen, S. L. W., Debets, R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.015 · Cited by 27
“Contradicting results regarding the relationship between tumour burden or disease stage and the risk of irAEs have been described for different tumour types [18,34,35].”
BackgroundResultCrompton, J. G., Gilbert, E., & Brady, M. S. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25343 · Cited by 20
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system
Michel, L., Totzeck, M., Lehmann, L., & Finke, D. (2020) · Herz · doi:10.1007/s00059-020-04954-8 · Cited by 20
Toor, K., Middleton, M. R., Chan, K., Amadi, A., Moshyk, A., & Kotapati, S. (2021) · BMC Cancer · doi:10.1186/s12885-020-07538-1 · Cited by 25
Self-citationMetabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications
Indini, A., Grossi, F., Mandalà, M., Taverna, D., & Audrito, V. (2021) · Biomedicines · doi:10.3390/biomedicines9060607 · Cited by 22
“Anti-PD1 treatment has recently become standard of care in the adjuvant setting for patients with resected stage III (pembrolizumab or nivolumab) or stage IV melanoma with no evidence of disease (nivolumab) [10,11].”
BackgroundCrosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 20
Eroglu, Z., Broman, K. K., Thompson, J. F., Nijhuis, A. A. G., Hieken, T. J., Kottschade, L. A., Farma, J. M., Hotz, M., Deneve, J. L., Fleming, M. D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004417 · Cited by 19
Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma
van Akkooi, A. C. J., Schadendorf, D., & Eggermont, A. M. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.022 · Cited by 20
Rare malignant neoplasm of the esophagus: current status and future perspectives
Yoshinami, Y., Nishimura, E., Hosokai, T., Yamamoto, S., Matsuda, S., Nomura, M., Kawakubo, H., Kato, K., & Kitagawa, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad144 · Cited by 21
“Both studies included a small number of patients with mucosal melanoma (84–86).”
BackgroundChan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J. W., Witteles, R. M., Nguyen, P. K. P., Cheng, P. P., & Zhu, H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01024-0 · Cited by 20
Egeler, M., Lai-Kwon, J. E., Tissier, R., Fraterman, I., Kuijpers, A. M. J., van Houdt, W. J., Wilgenhof, S., Rao, A. D., Sandhu, S. K., Lee, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113601 · Cited by 19
Varey, A. H. R., Li, I., Sharouni, M. E., Simon, J. M., Dedeilia, A., Ch’ng, S., Saw, R. P. M., Spillane, A. J., Shannon, K. F., Pennington, T. E., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01020 · Cited by 22
Self-citationImmune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
“…73 ), in comparison with PD-1/ PD-L1 blockade reported to cause high-grade adverse events from 10% to 15% of patients, over a range of doses, 74 indicating the improved tolerance of PD-1 75 Notably, clinical factors related to CRS are not well described and may often not be reported in the…”
ResultZabor, E. C., Coit, D. G., Gershenwald, J. E., McMasters, K. M., Michaelson, J. S., Stromberg, A. J., & Panageas, K. S. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6370-4 · Cited by 19
“Online prediction tools are particularly relevant in settings where standard of care is rapidly evolving, such as in melanoma, where effective adjuvant therapies are now treatment options for patients with stage III and IV resected melanoma.(2,3)”
BackgroundYokota, K., Uchi, H., Uhara, H., Yoshikawa, S., Takenouchi, T., Inozume, T., Ozawa, K., Ihn, H., Fujisawa, Y., Qureshi, A. H., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15103 · Cited by 20
Self-citationUse of Immuno-Oncology in Melanoma
Smylie, M. (2020) · Current Oncology · doi:10.3747/co.27.5135 · Cited by 19
Self-citationTreatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
Tikkanen, A., Iivanainen, S., & Koivunen, J. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03217-7 · Cited by 19
Ibrahim, A. M., May, M. L., Bossé, D., Marginean, H., Song, X., Nessim, C., & Ong, M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08407-8 · Cited by 19
Immuntherapie beim malignen Melanom
Zaremba, A., Zimmer, L., Griewank, K., Ugurel, S., Roesch, A., Schadendorf, D., & Livingstone, E. (2020) · Der Internist · doi:10.1007/s00108-020-00812-1 · Cited by 25
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 20
Heitmann, J. S., Walz, J. S., Pflügler, M., Kauer, J., Schlenk, R. F., Jung, G., & Salih, H. R. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039639 · Cited by 21
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
Ito, S., Tachimori, Y., Terado, Y., Sakon, R., Narita, K., & Goto, M. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02821-6 · Cited by 19
“Indeed, adjuvant therapy has been shown to increase recurrence-free survival (RFS) and to have varying effects on OS in patients with cutaneous melanoma [7].”
BackgroundPolishchuk, I., Yakobson, A., Zemel, M., Sharb, A. A., Shalata, W., Rosenberg, E., Kian, T. A., Alguayn, F., Peled, N., Rouvinov, K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0335 · Cited by 19
Placke, J., Soun, C., Bottek, J., Herbst, R. A., Terheyden, P. A. M., Utikal, J. S., Pföhler, C., Ulrich, J., Kreuter, A., Pfeiffer, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741993 · Cited by 20
Treatment of Metastatic Melanoma in the Elderly
Seedor, R. S., & Orloff, M. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01257-5 · Cited by 20
Leong, S. P. L., Wu, M. C., Lü, Y., Torre, D. M., von Bakonyi, A., Ospina, A. M., Newsom, J. D., Luckett, W. S., Soon, C. W. M., Kim, K. B., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6685-1 · Cited by 19
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
“Instead of adopting anti-CTLA-4 as adjuvant treatment, anti-PD-1 treatment with nivolumab [47] and later on with pembrolizumab [48], were established as effective strategies against disease recurrence, with improved toxicity profiles compared to ipilimumab.”
BackgroundMethodBreakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
Adler, N. R., Wolfe, R. S., McArthur, G. A., Kelly, J. W., Haydon, A. M., McLean, C., & Mar, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0088-8 · Cited by 19
Kanatsios, S., Melbourne Melanoma Project, Suen, C. S. N. L. W., Cebon, J. S., & Gyorki, D. E. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25138 · Cited by 19
“Furthermore, patients with resected stage IV melanoma have been eligible for a number of adjuvant studies.(21) Patient stratification with preoperative NLR in these studies should be considered.”
BackgroundAtkinson, T. M., Hay, J. L., Kim, S. Y., Schofield, E., Postow, M. A., Momtaz, P., Warner, A. B., Shoushtari, A. N., Callahan, M. K., Wolchok, J. D., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac266 · Cited by 18
Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
Miller, J. R., Lo, S., Nosrati, M., Stretch, J. R., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Nieweg, O. E., Ch’ng, S., Kim, K. B., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.6356 · Cited by 20
Looman, E. L., Cheng, P. F., Lai-Kwon, J. E., Morgan, L., Wakkee, M., Dummer, R., & Dimitriou, F. (2023) · Cancer Medicine · doi:10.1002/cam4.5967 · Cited by 20
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Profili, N. I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., & Delitala, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155161 · Cited by 19
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
Eljilany, I., Castellano, E., & Tarhini, A. A. (2023) · Cancers · doi:10.3390/cancers15164125 · Cited by 23
“Ipi 10 was not approved as an adjuvant therapy in Europe due to its association with a relatively high rate of trAEs, and the emergence of PD-1-inhibiting antibodies as a more efficacious and better tolerated adjuvant therapy for stage III melanoma patients [52].”
BackgroundReview of recent advances in managing periocular skin malignancies
Trotier, D., Huang, L., van Landingham, S. W., Burr, A. R., & Ma, V. T.-L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1275930 · Cited by 19
Immune Checkpoint Inhibitors in Geriatric Oncology
Cook, S. L., Amin, M. A., Bari, S., Poonnen, P. J., Khasraw, M., & Johnson, M. O. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01528-3 · Cited by 19
Revolutionizing treatment of advanced melanoma with immunotherapy
Carreau, N. A., & Pavlick, A. C. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.01.002 · Cited by 22
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Chanzá, N. M., Tripathi, A., & Harshman, L. C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0639-0 · Cited by 24
Cell-mediated immune resistance in cancer
Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 25
“Similarly optimistic results were shown in a phase 3 efficacy trial of adjuvant nivolumab against resected stage III or IV melanoma; however, the benefits observed with nivolumab were more significant than with ipilimumab (anti-CTLA-4), with additional concerns about the toxicity of the latter([144]).”
Result
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.